Quarterly report · Q1

Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥81.8bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥313.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.6bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.6bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥7.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.6bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥659m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥659m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥199.2bnat 2023-06-30Cons.Assets
Total assets¥185.3bnat 2023-03-31Cons.Assets
Total assets¥195.3bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2023-06-30Cons.Liabilities
Total liabilities¥128.8bnat 2023-03-31Cons.Liabilities
Net assets / equity¥56.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥56.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥23.8bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥22.062023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.922022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio28.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio30.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥3.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥3.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥1.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥72.3bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥72.3bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.6bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.6bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥5m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥484m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥10.5bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3.6bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥126m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥85.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥81.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥3.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥3.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 351
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任監査法人トーマツ
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)桃木 秀一 
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)佐野 明宏
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration74709000000JPY
Net sales (5-year summary)CurrentYTDDuration81848000000JPY
Net sales (5-year summary)Prior1YearDuration313318000000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration913000000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration1605000000JPY
Ordinary income loss (5-year summary)Prior1YearDuration7682000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration391000000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration659000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration4458000000JPY
Comprehensive income (5-year summary)Prior1YTDDuration395000000JPY
Comprehensive income (5-year summary)CurrentYTDDuration661000000JPY
Comprehensive income (5-year summary)Prior1YearDuration4456000000JPY
Net assets (5-year summary)Prior1QuarterInstant52897000000JPY
Net assets (5-year summary)CurrentQuarterInstant56771000000JPY
Net assets (5-year summary)Prior1YearInstant56483000000JPY
Total assets (5-year summary)Prior1QuarterInstant195341000000JPY
Total assets (5-year summary)CurrentQuarterInstant199201000000JPY
Total assets (5-year summary)Prior1YearInstant185297000000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration13.05
Basic earnings loss per share (5-year summary)CurrentYTDDuration22.06
Basic earnings loss per share (5-year summary)Prior1YearDuration148.92
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.2708
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.2850
Equity to asset ratio (5-year summary)Prior1YearInstant0.3048
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember32048000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember32048000
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant32048000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant32048000
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember2061400
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember29921700
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember299217
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember64900
Number of shares issued shares voting rightsCurrentQuarterInstant32048000
Number of voting rights issued shares voting rightsCurrentQuarterInstant299217
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member2061400
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member2061400
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0643

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass